Considering the prevention of metachronous gastric cancer in patients that already have extensive metaplastic gastritis, COX-2 inhibitors could induce the regression of precancerous lesions and prevent gastric cancer occurrence after H. pylori eradication. This evidence concerns the gene PTGS2 and gastric cancer.